Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05255276
- Locations
- 🇺🇸
Labcorp Drug Development Clinical Research Unit, Dallas, Texas, United States
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05134337
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of Soticlestat and Rifampin in Healthy Adults
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05098041
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05069688
- Locations
- 🇳🇬
University College Hospital/ University of Ibadan, Ibadan, Oyo State, Nigeria
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05069870
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05057949
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 550
- Registration Number
- NCT05047055
- Locations
- 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
- Conditions
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT04959266
- Locations
- 🇪🇸
Research Site, Malaga, Spain
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 732
- Registration Number
- NCT04951986
- Locations
- 🇿🇦
Mitchells Plain Hospital, Mitchells PLain, Cape Town, Western Cape, South Africa
🇿🇦Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha, Cape Town, Western Cape, South Africa
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933682
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.